initi coverag clinic lab
got failur commun
pama put wrench acceler growth thesi stunt price-to-earnings expans
broadli neutral posit clinic lab given improv
underli volum stabil price favor mix reason activ capit
deploy return pama alway contempl degre
risk worst case scenario ultim play make question
decis regard data set util decis notabl took wind
lab sail caus downward revis ep modest reset valuat
least stop multi-year expans track fundament
repriev possibl interim expect up-tick aid growth
enter fundament outsid medicar remain posit price
hit pama tough off-set particularli given cost structur alreadi
road optim said confid respect
manag team despit differ strategi weather initi headwind via
up-tick still grow respect rate furthermor stock
signific upsid exposur tax reform also provid valuat
back-stop see repriev pama cut possibl thu
stanc complex neutral current await broad updat
ep path forward preview pre tax reform low end lt guid given
favorit stock current lh
thing watch potenti pama repriev outreach cadenc omx
industri growth forecast macro indic point lsd core growth
complex trend appear slightli healthier suffer
hurrican induc interrupt see volum growth solidli rang
price weaker y-o-i due pama mix remain favor
would also note flu track prior year level may signal strong
start util standpoint
valuat price target across complex impli market cap weight price-to-earnings
ep reflect tax reform relat upsid termin growth rate
dcf primari valuat metric compar price-to-earnings rang
averag pleas note forecast current
ignor tax reform relat upsid ep dcf analysi adjust updat
cash tax rate thu view point valuat reflect tax reform pass
downsid risk potenti pama relat price hit translat
commerci pressur result neg flywheel effect margin increas
competit around health insur contract result price reset spook
investor yield neg multipl revis downshift econom activ
employ us post reform lead volum compress challeng ep
upsid risk provid price repriev realiz basket skew
incorrectli allow resumpt acceler growth path goal vertic
integr across healthcar complex lead view univers possess
strateg option long-term shift higher valu technolog
complex test creat new econom vertic well abil mine data
compani initi lh outperform
link webinar
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect
object report investor consid report singl factor make invest decis
initi coverag clinic lab
got failur commun
last page report import disclosur regard stock report
tabl content
iv bull bear debat thesi
threw wrench multi-year growth acceler thesi w/ tax reform provid upsid
broadli neutral posit clinic lab given improv underli
volum stabil price favor mix reason activ capit deploy return
pama alway contempl degre risk worst case scenario
ultim play make question decis regard data set util
notabl took wind lab sail caus downward revis ep modest
reset valuat least stop multi-year expans track fundament
enter fundament outsid medicar remain price hit pama
tough off-set particularli given cost structur alreadi road optim
said confid respect manag team despit differ
strategi weather initi headwind via up-tick still grow respect rate
furthermor stock signific upsid exposur tax reform also
provid valuat back-stop see repriev pama cut possibl
thu stanc complex neutral current await broad updat ep
path forward preview pre tax reform low end lt guid given rel valuat
favorit stock current lh
thing watch potenti pama repriev outreach cadenc omx trajectori
rel valuat point balanc risk reward across complex
macro indic point slight rise volum ye
clinic lab stock cont hc servic safe haven
flu activ spike start season
googl trend point recoveri lab volum
medic lab spend continu step
metric appear reason best case resumpt rel expans tie repriev
risk point balanc risk reward profil price uncertainti vs stabl volum tax reform
potenti pama relat price hit translat commerci pressur result neg flywheel effect margin
increas competit around health insur contract result price reset spook investor yield multipl
downshift econom activ employ us post reform lead volum compress challeng ep trajectori
provid price repriev realiz basket skew incorrectli allow resumpt acceler growth path
goal vertic integr across healthcar complex lead view univers possess strateg option long-term
shift higher valu technolog complex test creat new econom vertic well abil mine data
bull bear debat thesi
bull bear debat skew neutral post
 activ up-tick
tax reform upsid
pama stay
thesi
attract asset despit nt pama headwind core
acceler growth stunt pama w/ solid execut tax
reform enough bia valuat upward
laboratori corp america hold
initi outperform pt
price wrong
last page report import disclosur regard stock report
tabl content
debat big headwind pama prove
debat chiltern address cvd limitations/help growth
debat m-lt outlook omx
point differenti vs st
iv valuat risk tax reform vs price risk
 conclus initi outperform thesi
lh perform larg track
lead life scienc compani one largest
independ clinic laboratori provid drug
develop servic biopharma client
chiltern lab tuck-in deal help off-set
pama hit valuat still reason
rate valuat pt outperform pt
ebitda vs average
price-to-earnings vs average
risk pama relat price haircut roll
commerci creat virtuou circl margin pressur
revenu split clinic lab/cro
manag team year industri experi
previous head lh diagnost hospit
health system group
spent year quintil cfo
debat big headwind pama prove
outcom surpris given mani lab includ
pama result sizeabl hw lh
pama controversi start cmss desir
cmss decis estim lh total revenu
conduct market-bas survey lab price
hit bp
lab servic one area
govern pay above-market price
waffl whether includ hospit outreach
lab market much higher rate
septemb announc hospit lab
would includ rate calcul
mean lh repres disproportion
calcul result overal much lower
pama rollback possibl uptick like
price cut probabl realiz
somewhat unusu issu multi-year price
possibl agenc revisit pama
provid relief futur year
dgx/lh independ lab
market mani smaller competitor higher
cost structur therefor like
hurt pama
smaller lab alreadi
bar pama repriev like see small
lab sale correspond decreas price paid
pama unpleas dgx/lh manag potenti disastr small lab
revenu impact total drop downtax affect hit januari
award premium consistency/dividend
lh trade discount
dgx improv perform current manag
dividend piqu investor interest also caus
stock screen posit lot quant fund
comparison lh screen well
hamper earli perform bumpi
respect covanc central lab roll pre deal
lh manag sinc done lot work
turn asset around see question
midst becom broad-bas life
ultim lh strategi work
differ reason appeal differ base
strategi matur acceler growth multipl
multipl begin trend upward mt
ceo comment acquisit
integr part strateg growth expect lh
remain highli acquisit transform
given bn /year convers
compani like continu
acquir tuck-in lab larger cro asset
also model mm repo
ultim strategi gener revenu growth
per year hsd ep growth would bia
multipl higher strategi gain momentum
plenti exampl strong gener entiti
perform improv consist believ investor reward lh
debat chiltern address cvd limitations/help growth
chiltern bring small biopharma client
chiltern strong key oncolog vertic
chiltern bolster geograph presenc apac region
pf organ better suit realiz promis integr lab/cro
debat m-lt outlook omx
launchpad success expect upsiz
expand launchpad covanc busi
continu expans constant improvement/combat
pama see omx w/ mix determin magnitud
robust permit cap alloc boost core
impact lab margin besid pama
mix shift toward higher complex test
posit time
acq depress asset via tuck
long-term margin accret though st
mix impact covanc margin
chiltern lower margin given larger
busi lower margin substanti
increas trial complex also depress
om weigh mix/pama total profit growth remain strong
model summari point differenti vs street
swing factor pama repriev cvd omx trajectori pace outreach
point differenti
larg in-lin
conserv view
launchpad cvd
step-up help partial
ep slightli st
in-lin
reform
respect financi perform spite pama w/ tax reform net
million except per share data fy end septemb volum organ gp growth revenu margin ep share net incom price-to-earnings premium/discount januari
metric remark consist despit underli improv shift toward high growth vertic
risk point favor risk reward profil heighten price pressur vs pama repriev tax reform
potenti pama relat price cut bleed commerci price ultim lead neg margin cycl
recent vertic integr hc servic organ lead increas price pressur given heighten focu unit cost
challeng associ integr small outreach lab deal could depress return invest capit prove distract
effort off-set pama cut increas cost save could yield servic challeng ultim depress core organ volum
poor perform major clinic trial could harm cvd reput lead signific shift cro relat market share
signific downtick biotech relat fund could lead materi growth downshift earli phase demand harm profit
dcf valuat yield price
dcf deriv pt impli termin growth rate impli ebitda multipl
assumpt underli dcf valuat methodolog
year ebita margin assumpt
termin ebitda multipl
wacc base beta risk free rate cost debt
tax rate assum vs pre tax reform
assumpt impli termin growth rate
discount ebitda termin free flow enterpris total valu valu per lh perpetu growth valu enterpris enterpris valu januari
conclus initi outperform pt upsid
attract asset despit nt pama headwind core growth improv reform support multipl
notabl posit share lh thesi cro trend would trend
veli increas lab activ strong underli core would aid multipl
except lh end moder size cro asset chiltern vs
sizeabl deal like prxl ppdi major surpris one pama
struggl logic end ultim price approach
cut stay model adjust realiti multi-year profit reset
said see hit manag particularli given numer posit factor
busi also given likelihood acceler manag outreach thesi
term factor would point strong book momentum cvd
off-set continu launchpad save chiltern synergi captur strong underli volum
also see reason ep upsid valuat support tax reform help
sustain ep momentum lieu deeper pama relat cut set
thu discount market in-lin w/ histor norm see appeal entri point
share potenti upsid risk also potenti relief pama
addit would point multi-year transform lh current undergo
diversifi life scienc provid ultim bia rel multipl higher
given dynam see risk reward favor thu initi share o/p rate
thing watch revisit pama cvd book momentum omx trajectori
initi pt
last page report import disclosur regard stock report
